ClinicalTrials.gg
RecruitingNCT05750992Updated Jan 6, 2026

Ultrasound Guided TAPB vs Surgical TAPB With Bupivacaine in Cesarean Section

An interventional study of surgical TAP block and US guided TAP block in Cesarean Section, Ultrasound Guided Transversus Abdominis Plane Block and Surgical Transversus Abdominis Plane Block, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Open to female participants aged 21 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Acute Pain with a site in Egypt — 6 open to participants now, 6 under way, none of them phase 3. Acute Pain · Egypt.

Planned enrollment
32nd of 40
50 · median 77
Started
2023
with 2 others
No phase
28 of 40
6 open now
Registered
32nd of 40
by date
Lead sponsor
1 of 40
Al-Azhar University

Among the 40 studies in Acute Pain with a site in Egypt, this one is the 32nd largest by planned enrollment, is one of 3 that started in 2023, is one of 28 with no phase, and was the 32nd registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

6 of the 40 studies in Acute Pain with a site in Egypt are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 21 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Acute Pain with a site in Egypt, or all of them as a file.
02

Study summary

The aim of this study is to compare Surgical Transversus abdominis plane block and Ultrasound guided transversus abdominis plane block (TAPB) as a postoperative analgesic regimen in female patients undergoing elective cesarean delivery.

Read the detailed description

Caesarean delivery rates have been increasing worldwide nowadays. At rate of [52%], Egypt stands out among countries with the world's highest cesarean delivery percentages . Within the Arab region, rate of cesarean section far higher in Egypt than other Arab countries.

A much simpler and theoretically superior means of establishing a TAP block. When using a transcutaneous (conventional) approach there is always the risk of peritoneal puncture with its attendant complications. Moreover, there are technical difficulties, especially in obese women and the procedure requires specialist equipment, a skilled operator and training in ultrasonography. Our approach obviates these risks and difficulties because the procedure is carried out under direct vision, and it is much easier to perform by the surgeon during caesarean section.

03

Conditions studied

  • Cesarean Section
  • Ultrasound Guided Transversus Abdominis Plane Block
  • Surgical Transversus Abdominis Plane Block
  • Bupivacaine
  • Acute Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Full term pregnant women
  • Older than 21 years of age
  • Had elective cesarean section with Pfannenstiel incision.

Exclusion criteria

Exclusion Criteria:

  • Patients with cesarean section using different surgical incision
  • History of addiction [including opioids and benzodiazepines]
  • Allergy to the anesthetic analgesia
  • Psychological disorders
  • Coagulopathies
  • Infection at the block injection site.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    surgical TAP block

    twenty-five pregnant women will receive surgical TAP block performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.

    Procedure: surgical TAP block

  • Active comparator
    US guided TAP block

    25 pregnant women will receive US guided T.A.P block performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.

    Procedure: US guided TAP block

Interventions

  • Proceduresurgical TAP block

    performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.

    Also known as: bupivacaine, normal saline, fentanyl, pethidine

  • ProcedureUS guided TAP block

    performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.

    Also known as: bupivacaine, normal saline, fentanyl , pethidine

06

What researchers measure

Primary outcomes

  1. Time to perform block.

    The time taken to perform the block will be recorded by an independent observer.

    Time frame: 1 hour postoperatively

Secondary outcomes

  1. Heart rate

    Patients hemodynamics (heart rate will be recorded)

    Time frame: 24 hours postoperatively

  2. Mean arterial blood pressure

    Patients hemodynamics (mean arterial blood pressure will be recorded)

    Time frame: 24 hours postoperatively

  3. Pain score

    The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: 24 hours postoperatively

  4. Time to first analgesic request

    The time to first analgesic request will be recorded

    Time frame: 24 hours postoperatively

  5. Amount of post operative analgesic consumption

    The amount of post operative analgesic consumption will be recorded

    Time frame: 24 hours postoperatively

  6. Time spent in operating room

    The time spent in operating room will be recorded

    Time frame: 24 hours postoperatively

  7. Incidence of Adverse reactions

    Adverse events will be recorded such as nausea, vomiting, hypotension (Mean arterial blood pressure \< 20% of baseline readings and will be managed by ephedrine 5 mg IV and/or normal saline IV) and bradycardia (heart rate \< 60 beats/min and will be managed by atropine 0.6 mg IV).

    Time frame: 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Kohaf
    Cairo, 11865, Egypt
    Recruiting
    • Neveen A. Kohaf, Ph.D · Contact01069482380
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon reasonable request from the principle investigator

Supporting information: Study protocol, Statistical analysis plan

Time frame: for one year after completion of the study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 44 months is above that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2023
First posted
Mar 2, 2023
StartActual
Apr 10, 2023
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05750992
Responsible party
Neveen Abd El Maksoad Kohaf (Lecturer of Clinical Pharmacy, Al-Azhar University) — Principal investigator
First posted
Mar 2, 2023
Start date
Apr 10, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jan 6, 2026

Study contacts

Neveen A. Kohaf, Ph.D
Contact
nevenabdo@azhar.edu.eg
+201069482380

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion